Lyell Immunopharma, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lyell Immunopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $0.00.
- Lyell Immunopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $26.00K.
- Lyell Immunopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was -$1.00K, a 100.66% decline year-over-year.
- Lyell Immunopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Lyell Immunopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $42.00K, a 72.73% decline from fiscal 2024.
- Lyell Immunopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $154.00K, a 49.67% decline from fiscal 2023.
- Lyell Immunopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $306.00K, a 96.80% decline from fiscal 2022.
- Lyell Immunopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $9.58M, a 1.43% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2026-03-31 | $26.00K 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $42.00K 10-K · filed 2026-03-12 | |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $154.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $306.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $52.00K 10-Q · filed 2025-08-12 | $378.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $103.00K 10-Q · filed 2025-05-13 | $409.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $151.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $306.00K 10-K · filed 2026-03-12 |
| 2023-09-30 | $72.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $83.00K 10-Q · filed 2024-08-07 | |
| 2022-12-31 | $325.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $9.58M 10-K · filed 2025-03-11 |
| 2022-09-30 | $5.13M 10-Q · filed 2023-11-07 | $16.65M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $1.57M 10-Q · filed 2023-08-08 | $12.05M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $2.56M 10-Q · filed 2023-05-04 | $11.11M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $7.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $9.44M 10-K · filed 2024-02-28 |
| 2021-09-30 | $529.00K 10-Q · filed 2022-11-08 | $2.38M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $630.00K 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $884.00K 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $373.00K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |